6.66  -0.02 (-0.3%)		12-15 15:59
Open: 6.9 High: 7.06 Volume: 687,358		Pre. Close: 6.68 Low: 6.56 Market Cap: 332(M)

Short term
Mid term
Targets	6-month :	8.24	1-year :	9.63
Resists	First :	7.05	Second :	8.24
Pivot price	6.04
Supports	First :	6.09	Second :	5.5
MAs	MA(5) :	6.27	MA(20) :	6
	MA(100) :	6.47	MA(250) :	0
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	82.8	D(3) :	73
RSI	RSI(14): 60
52-week	High :	10.72	Low :	4.8

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CYBN ] has closed below upper band by 0.9%. Bollinger Bands are 2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.06 - 7.1	7.1 - 7.13
Low:	6.48 - 6.52	6.52 - 6.54
Close:	6.6 - 6.66	6.66 - 6.71

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Fri, 12 Dec 2025
Cybin (OTCMKTS:CYBN) Trading 5.5% Higher - Should You Buy? - MarketBeat

Fri, 28 Nov 2025
Cybin Announces Up to USD$35 Million At-The-Market Equity Program - Investing News Network

Thu, 20 Nov 2025
Cybin (CYBN) Analyst Rating Update: Canaccord Genuity Lowers PT to $45 | CYBN Stock News - GuruFocus

Thu, 20 Nov 2025
Canaccord Genuity Maintains Cybin (CYBN) Buy Recommendation - Nasdaq

Thu, 20 Nov 2025
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - Yahoo Finance

Mon, 17 Nov 2025
Cybin stock price target lowered to $55 by H.C. Wainwright on timeline shifts - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.